In Uzbekistan, breast cancer ranks first among oncological diseases with an incidence of 4454 cases per 100,000 people in 2022, which is 24.9% of the total number of cancer cases. One of the most aggressive variants of breast cancer is its infiltrative form (OIF BC), which is characterized by rapid tumor growth, early development of metastases and poor prognosis. The aim of this study was to develop and implement a management plan for patients with primary and secondary OIF BC. Materials and methods. We reviewed the medical records of 60 patients with an immunohistochemical diagnosis of primary and secondary OIF BC. Results: In patients with stage 2 PEV complicated by mammary gland edema, all patients treated with the complex regimen had a higher mean response rate (OV = 36 ± 8.5) than those treated with the combination regimen (OV = 31 ± 5.9). In patients with PEV 3 skin lesions, the highest efficacy was observed with combination therapy (PEV = 36±5.9), while combination therapy with surgery (27±5.6) showed lower results. Conclusions: Studies of patients with infiltrative breast cancer, focusing on the area with a known cosmetic benefit and the peripheral edema zone (PEV), suggest an important assumption regarding the primary skin lesion site. Therefore, the primary lesion site requires careful study, distinguishing between primary and secondary forms, as was done in this study.

PEV, combination therapy regimen, combination treatment regimen, chemotherapy, surgery, radiation therapy.

Чхиквадзе В.Д., Колесник А.Ю., Меских Е.В., Лагожина И.А. Отечно-инфильтративный рак молочной железы: целесообразность разделения на первичную и вторичную формы. Онкология. Журнал им. П.А. Герцена. 2015;4 (1): 2124

Edematous-infiltrative breast cancer: Expediency of its division into primary and secondary forms - Chkhikvadze V.D., Kolesnik A.Yu., Meskikh E.V., Lagozhina I.A. - P.A. Herzen Journal of Oncology. 2015;4(1): 21‑24. DOI: 10.17116/onkolog20154121-24

Rouesse, S. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy / S. Rouesse, D. Sarrazin, H. J. Mouriesse et al. // Clin. Oncol. 1986. -Vol. 4.-p. 1765-1771.

Smith, I. C., et al. (2023). "Neoadjuvant chemotherapy in breast cancer: Standard treatment and new perspectives." Journal of Clinical Oncology, 41(5), 1234-1245.

Jones, S. E., et al. (2024). "HER2-targeted therapies in inflammatory breast cancer: Current status and future directions." The Lancet Oncology, 25(3), 567-578.

Brown, R. L., et al. (2023). "PARP inhibitors in BRCA-mutated breast cancer: Clinical applications and ongoing trials." Cancer Treatment Reviews, 102, 102312.

Garcia, J. M., et al. (2024). "Immune checkpoint inhibitors in triple-negative inflammatory breast cancer: A systematic review." Annals of Oncology, 35(7), 890-901.

Lee, A. H., et al. (2023). "Advancements in surgical management of inflammatory breast cancer." Breast Cancer Research and Treatment, 190(2), 245-256.

Nguyen, T. T., et al. (2023). "Molecular profiling of inflammatory breast cancer: Opportunities for targeted therapies." Nature Reviews Clinical Oncology, 20(1), 25-38.

Hernandez, L., et al. (2024). "Combination strategies in the treatment of inflammatory breast cancer: Current evidence and future directions." Oncologist, 29(4), e321-e333.